News

Rib-X Pharmaceuticals (Rib-X) has entered into a collaborative research agreement with Massachusetts General Hospital (MGH). Under the science plan for the collaboration, David Hooper of MGH will evaluate

Biovitrum has announced that the first patient was dosed in a Phase I/IIa study of its long-acting fully-recombinant Factor VIII Fc fusion (rFVIIIFc) protein. The Phase I/IIa open-label

SRI International has received the US patent 7592021 for a new bioadhesive drug delivery system that enables enhanced release of drugs through the human body’s mucous membranes. The

US-based Alvogen has established operations in Asia and has opened an office in Shanghai, China that will lead efforts to commercialize the company’s products in the country. Alvogen

The FAD has approved the experimental use of Diamyd vaccine in children as young as 3 years of age in the TrialNet GAD study, enrolling 126 new onset

AstraZeneca has entered into a framework agreement with EDB that makes EDB one of the company’s selected suppliers in the IT services area. AstraZeneca has decided to consolidate

Callidus has announced a partnership with Seven Seas Technologies, a provider of integrated business and technology solutions. Under the agreement, Seven Seas Technologies will resell, implement and support

Upp Technology has implemented its irmsEM (Emergency Management) software for the State of Vermont within three weeks of selection of the solution. The software helped the State’s RSS

Active Biotech has achieved primary end point in ongoing Phase II clinical trial of TASQ, in patients with asymptomatic, castrate resistant, metastatic prostate cancer. The first analysis of